AstraZeneca has officially canceled its planned £450 million investment in a Merseyside vaccine manufacturing plant, citing inadequate support from the Labour government compared to previous offers made by the former Conservative administration. This decision reverses prior plans announced in the March budget to expand the pharmaceutical company’s operations, aimed at enhancing public health and pandemic preparedness in the UK. While the existing facility will remain operational and no jobs are at risk, the cancellation represents a significant setback for the government's aspirations to bolster the life sciences sector in the country.
In a significant reversal, AstraZeneca has canceled a planned £450 million investment in a vaccine manufacturing plant due to insufficient government support, impacting the UK's life sciences sector.
The cancellation of AstraZeneca's investment highlights the reliance of the UK pharmaceutical industry on governmental support for growth and development, especially in strategic areas like vaccine manufacturing.
Collection
[
|
...
]